US Market News
7日前
HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of ScheduleJuly 1, 2026 1:05 PM
Business WireAccelerated enrollment completion in ALIGN-ACS study underscores HeartBeam’s execution on its key strategic priority of heart attack detectionData analysis is underway, with full results anticipated for presentation at upcoming cardiology conferenceFindings will inform the design of the planned U.S. pivotal study and support the FDA pathwayFuture indication expansion could unlock a large addressable market of millions of patients at riskHeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through powerful cardiac insights, today announced completion of patient enrollment in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. Enrollment was completed ahead of the Company’s previously communicated third quarter 2026 timeline.Heart attacks remain a leading cause of death in the United States, with millions of patients at elevated risk. Patients with heart attack symptoms often delay seeking care for more than 2 hours1 because the symptoms can be vague or subtle, which contributes to higher mortality, more complications, and greater care costs. HeartBeam’s 3D ECG technology is designed to allow patients to record a clinical-grade ECG at the onset of symptoms, wherever they are, with the goal of shortening symptom-to-door times and supporting faster, more informed care decisions outside a clinical setting.“Completing enrollment ahead of schedule reflects both the quality of the study design and the operational discipline our team has built, providing us a strong foundation as we move into pivotal study planning,” said Branislav Vajdic, Ph.D., Founder and President of HeartBeam. “We believe the data from the ALIGN-ACS pilot study will be an important input into our discussions with the FDA, and we are evaluating whether this milestone supports a more accelerated path toward an expanded indication for heart attack detection. We look forward to sharing full results later this year and advancing this program with the same discipline and pace our team has demonstrated throughout this study.”The study enrolled 120 patients presenting with chest pain in the emergency department across two clinical sites in Belgrade, Serbia. Patients were evaluated with both a standard 12-lead ECG and the HeartBeam System, with physician assessment for acute coronary syndrome using both ECG modalities compared against an independently adjudicated clinical-data-based gold standard. Data analysis is underway, and the Company plans to present the results at a major cardiology conference in the coming months.Results from the ALIGN-ACS pilot study are intended to inform the design of a planned pivotal study in the United States and support a future FDA submission seeking to expand the HeartBeam System’s indication beyond arrhythmia assessment to include heart attack assessment. The Company plans to use learnings from the pilot, together with prior proof-of-concept data, including a study recently published in JACC: Advances, to inform upcoming discussions with the FDA regarding the design and scope of the pivotal program.This milestone reinforces HeartBeam’s focus on its path toward an expanded indication for heart attack detection and its broader platform strategy. The Company’s long-term vision is to make its potentially life-changing system available to as many patients as possible, as quickly as possible.About HeartBeam, Inc.HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2025**. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.Forward-Looking StatementsAll statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.References:1. De Luca G. Circulation. 2004 Mar 16;109(10):1223-5, Heidenreich PA, J Card Fail. 2022 Mar;28(3):453-466**Cleared Indications for Use:
The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment only. The heart attack detection indication is not FDA cleared and not available in the US or any other geography at this time. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.MKT-152 v0View source version on businesswire.com: https://www.businesswire.com/news/home/20260630151674/en/Media Contact:
media@heartbeam.comInvestor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us Original: HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule
US Market News
2週前
HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership TransitionJune 24, 2026 4:05 PM
Business Wire Company will license its 3D ECG signal technology to established partners, moving beyond direct medical device sales Advancing toward heart attack detection as a key expansion of the platform Tailoring its technology to fit each market, while operating with a leaner, more focused structure Company to provide more details on strategy as part of Second Quarter 2026 conference call in August HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a reorganization to prioritize global market reach and capital efficiency while accelerating execution. The company has aligned its operations around focused implementation teams which will be led by Branislav Vajdic, Ph.D., Founder and President, and Rich Ferrari, Executive Chairman. The teams are focused on a single goal: to provide every at-risk cardiac patient access to HeartBeam’s groundbreaking technology. This structure streamlines decision-making, improves accountability, and enables leadership to concentrate resources on achieving key milestones while maintaining disciplined management. The reorganization is expected to sharpen the Company’s focus on delivering results and create a meaningfully lower cost structure. As part of these changes, Robert Eno, former Chief Executive Officer, will transition to a consulting role for HeartBeam. “Our mission is to drive widespread global adoption of our breakthrough technology,” said Ferrari. “We thank Rob for bringing HeartBeam to this point, from securing FDA clearances to establishing the commercial foundation that makes this next phase possible. Now, we are streamlining our operations and broadening our reach so that this potentially life-changing system can get into the hands of as many patients as possible, as quickly as possible.” The reorganization will enable the company to focus on the key deliverables which separate it from the crowded cardiac monitoring space, namely: An AI-ready signal, built for more than cardiac care. AI can only deliver actionable insight based on the quality of the signal it is given. HeartBeam has built what it believes is the best ambulatory ECG signal-acquisition platform — a data-rich 3D signal that is the input AI needs to move from inference to true detection. This broader platform strategy has been made possible most recently by the rapid advance of AI: the Company can now extract remarkably accurate, clinical-grade recordings directly from its groundbreaking 3D signal-acquisition and ECG processing platform — turning more than a decade of signal science into an immediately actionable foundation. Moreover, the company believes this same signal quality can serve third-party AI platforms being developed across medicine that depend on high-quality, real-world ECG data. Advancing toward heart attack detection. A central focus of this strategy is expanding HeartBeam's platform beyond arrhythmia assessment into reliable heart attack detection, which the company believes is one of the largest unmet needs in cardiac care. The company continues to build the evidence base needed to pursue this expanded indication and believes this milestone will make its device a must-have for every cardiac patient, with the potential to save millions of lives and billions of dollars in avoidable medical costs. One platform, every market. HeartBeam intends to achieve global adoption by partnering its breakthrough patented 3D ECG platform across the five channels that already have distribution — governments and national health systems, ECG OEMs, Holter and patch manufacturers, health systems and integrated delivery networks, and consumer wearable companies — and by adapting its technology to the form factor each use case requires. The company believes its technology can be adapted to multiple form factors: a ruggedized unit that lets a rural health clinic triage a patient in minutes, an adhesive patch for longer-term monitoring, a simpler form factor for an older or less agile patient, or a sleek, compact card an expert user slips into a wallet. The company received FDA marketing clearance for its synthesized 12-lead ECG signal for arrhythmia assessment in December 2025 giving physicians a familiar format they already trust. The company believes this unique capability will be critical to adoption in many use cases. “HeartBeam's technology addresses a fundamental gap in cardiac care: the ability to get a verified, clinical-grade ECG reading anywhere, at any time, without a clinic visit. With commercialization underway, the company is positioned to make that capability routine for the millions of Americans living with or at risk for arrhythmia,” said Dr. Vajdic. “At the same time, we will continue to conduct the previously announced clinical studies to accelerate the development of our offering into a comprehensive detection platform for heart attack and other cardiac conditions beyond arrhythmia.” About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com. Forward-Looking Statements All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. 1Cleared Indications for Use The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment only. The heart attack detection indication and algorithm are not FDA cleared and not available in the US or any other geography at this time. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology. MKT-152 v0 View source version on businesswire.com: https://www.businesswire.com/news/home/20260624011757/en/ Media Contact:
media@heartbeam.com Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us Original: HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition
georgie18
1月前
BEAT...93...🥳...Getting some traction here...
georgie18
Re: georgie18 post# 400
Thursday, May 14, 2026 8:29:47 AM
Post#
401
of 401
BEAT...$1.09...🥳...Gappa...
georgie18
Re: None
Wednesday, May 13, 2026 3:04:00 PM
Post#
400
of 400
BEAT...$1.02...🥳...Break/Hold $1.12 and see will RIP...imo... we shall see...
georgie18
Re: None
Wednesday, May 13, 2026 2:10:14 PM
Post#
722136
of 722165
BEAT...$1.00...🥳...Upper Bollie Break...
georgie18
Re: georgie18 post# 396
Friday, April 17, 2026 10:39:59 AM
Post#
397
of 398
BEAT...99...🥳...Filling the open gap here...
georgie18
Re: georgie18 post# 395
Friday, April 17, 2026 9:43:10 AM
Post#
396
of 396
BEAT...9630...🥳
georgie18
Re: georgie18 post# 393
Friday, April 17, 2026 8:36:53 AM
Post#
395
of 395
BEAT...89s clearing here...🥳...bought the .80 range offering dip...
georgie18
Re: US Market News post# 392
Wednesday, April 15, 2026 8:45:37 AM
Post#
393
of 394
BEAT...88...🥳...Buying Dips on offering... HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock
April 14, 2026 10:00 PM
Business Wire
Offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock for total gross proceeds of $10 million, before deducting underwriting discounts, commissions, and offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions.
The offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, existing investors, and several fundamental institutional investors.
georgie18
2月前
BEAT...$1.09...🥳...Gappa...
georgie18
Re: None
Wednesday, May 13, 2026 3:04:00 PM
Post#
400
of 400
BEAT...$1.02...🥳...Break/Hold $1.12 and see will RIP...imo... we shall see...
georgie18
Re: None
Wednesday, May 13, 2026 2:10:14 PM
Post#
722136
of 722165
BEAT...$1.00...🥳...Upper Bollie Break...
georgie18
Re: georgie18 post# 396
Friday, April 17, 2026 10:39:59 AM
Post#
397
of 398
BEAT...99...🥳...Filling the open gap here...
georgie18
Re: georgie18 post# 395
Friday, April 17, 2026 9:43:10 AM
Post#
396
of 396
BEAT...9630...🥳
georgie18
Re: georgie18 post# 393
Friday, April 17, 2026 8:36:53 AM
Post#
395
of 395
BEAT...89s clearing here...🥳...bought the .80 range offering dip...
georgie18
Re: US Market News post# 392
Wednesday, April 15, 2026 8:45:37 AM
Post#
393
of 394
BEAT...88...🥳...Buying Dips on offering... HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock
April 14, 2026 10:00 PM
Business Wire
Offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock for total gross proceeds of $10 million, before deducting underwriting discounts, commissions, and offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions.
The offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, existing investors, and several fundamental institutional investors.
georgie18
2月前
BEAT...$1.02...🥳...Break/Hold $1.12 and see will RIP...imo... we shall see...
georgie18
Re: None
Wednesday, May 13, 2026 2:10:14 PM
Post#
722136
of 722165
BEAT...$1.00...🥳...Upper Bollie Break...
georgie18
Re: georgie18 post# 396
Friday, April 17, 2026 10:39:59 AM
Post#
397
of 398
BEAT...99...🥳...Filling the open gap here...
georgie18
Re: georgie18 post# 395
Friday, April 17, 2026 9:43:10 AM
Post#
396
of 396
BEAT...9630...🥳
georgie18
Re: georgie18 post# 393
Friday, April 17, 2026 8:36:53 AM
Post#
395
of 395
BEAT...89s clearing here...🥳...bought the .80 range offering dip...
georgie18
Re: US Market News post# 392
Wednesday, April 15, 2026 8:45:37 AM
Post#
393
of 394
BEAT...88...🥳...Buying Dips on offering... HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock
April 14, 2026 10:00 PM
Business Wire
Offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock for total gross proceeds of $10 million, before deducting underwriting discounts, commissions, and offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions.
The offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, existing investors, and several fundamental institutional investors.
georgie18
2月前
BEAT...$1.00...🥳...Upper Bollie Break...
georgie18
Re: georgie18 post# 396
Friday, April 17, 2026 10:39:59 AM
Post#
397
of 398
BEAT...99...🥳...Filling the open gap here...
georgie18
Re: georgie18 post# 395
Friday, April 17, 2026 9:43:10 AM
Post#
396
of 396
BEAT...9630...🥳
georgie18
Re: georgie18 post# 393
Friday, April 17, 2026 8:36:53 AM
Post#
395
of 395
BEAT...89s clearing here...🥳...bought the .80 range offering dip...
georgie18
Re: US Market News post# 392
Wednesday, April 15, 2026 8:45:37 AM
Post#
393
of 394
BEAT...88...🥳...Buying Dips on offering... HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock
April 14, 2026 10:00 PM
Business Wire
Offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock for total gross proceeds of $10 million, before deducting underwriting discounts, commissions, and offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions.
The offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, existing investors, and several fundamental institutional investors.
US Market News
2月前
HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge PracticeMay 7, 2026 8:31 AM
Business Wire Leading concierge practice Atelier Health, led by physicians affiliated with Cedars-Sinai, will now offer HeartBeam to its patients Opens up flagship sites across New York, Dallas, South Florida and Southern California, supporting scalable expansion of HeartBeam technology in preventive cardiology HeartBeam continues to execute on its go-to-market strategy in high-value, direct-pay care environments HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a commercial agreement with Atelier Health, a premier concierge medical practice led by physicians affiliated with Cedars-Sinai Medical Center. The addition of Beverly Hills-based Atelier Health expands HeartBeam’s commercial footprint across four targeted launch markets – New York metro, Dallas, South Florida, and Southern California – completing an initial geographic footprint to advance the Company’s scalable go-to-market strategy in concierge and preventive cardiology. The collaboration underscores HeartBeam’s positioning within the high-value direct pay healthcare segment where adoption of innovative technologies can occur more rapidly and patients are seeking proactive cardiac insights tailored to their individual risk profiles. Through its recently announced partnership with ClearCardio™, the Company has also established its initial presence in New York metro, Dallas, and South Florida. Atelier Health extends the network to Southern California, establishing HeartBeam’s initial commercial footprint across its targeted launch markets and providing a foundation for broader national expansion. Atelier Health, which is expanding its Beverly Hills presence with enhanced imaging capabilities and rebranding as Generational Health, offers individualized preventive and diagnostic programs supported by advanced medical protocols, specialist-level access and world-class technology. Co-founder Ram Dandillaya, MD, who previously served as Clinical Chief of Cardiology at Cedars-Sinai for 8 years, and his patients previously participated in HeartBeam’s Early Access Program, gaining firsthand experience with the Company’s patented cable-free 3D ECG technology. By capturing the heart’s electrical signals in three non-coplanar dimensions and synthesizing them into a 12-lead ECG, HeartBeam enables patients to obtain high-fidelity, clinical-grade ECG data for arrhythmia assessment from the comfort of home. “Prevention is foundational to how we care for patients, which requires access to high-quality, meaningful data beyond the clinic,” said Dr. Dandillaya. “Our model is built on delivering the highest standard of specialist care with unmatched access and precision, and HeartBeam’s technology enables a more proactive, personalized approach to evaluating cardiac symptoms in real-world settings.” “The addition of Atelier Health reflects the growing momentum behind our commercialization strategy,” said Robert Eno, Chief Executive Officer of HeartBeam. “With flagship sites now established across our initial launch markets, we are building a strong foundation for scalable growth. We believe partnering with leading concierge and preventive cardiology practices will continue to accelerate adoption of the HeartBeam System and expand access to clinical-grade cardiac insights beyond traditional care settings.” This partnership advances HeartBeam's commercialization strategy across the concierge and preventive cardiology segment while validating its subscription-based business model. With multiple customers now established across key geographies, HeartBeam is building a repeatable model designed to support broader national expansion. About Atelier Health Atelier Health is a concierge medical practice based in Beverly Hills, California, delivering specialist-led healthcare with a focus on personalized prevention and treatment. The practice provides patients with 24x7x365 access to expert care, offering individualized programs supported by advanced medical protocols and world-class technology. Atelier Health’s physicians are affiliated with Cedars-Sinai Medical Center, which has been recognized by U.S. News & World Report as one of America’s Best Hospitals. Atelier Health’s mission is to deliver compassionate, family-centered care while providing patients access to the highest standard of U.S.-based specialty medicine. Visit https://atelier90210.com/ for more information. About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com. Forward-Looking Statements All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. 1Cleared Indications for Use The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology. MKT-143 v0 View source version on businesswire.com: https://www.businesswire.com/news/home/20260507972967/en/ Media Contact:
media@heartbeam.com Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us Original: HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge Practice
georgie18
3月前
BEAT...99...🥳...Filling the open gap here...
georgie18
Re: georgie18 post# 395
Friday, April 17, 2026 9:43:10 AM
Post#
396
of 396
BEAT...9630...🥳
georgie18
Re: georgie18 post# 393
Friday, April 17, 2026 8:36:53 AM
Post#
395
of 395
BEAT...89s clearing here...🥳...bought the .80 range offering dip...
georgie18
Re: US Market News post# 392
Wednesday, April 15, 2026 8:45:37 AM
Post#
393
of 394
BEAT...88...🥳...Buying Dips on offering... HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock
April 14, 2026 10:00 PM
Business Wire
Offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock for total gross proceeds of $10 million, before deducting underwriting discounts, commissions, and offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions.
The offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, existing investors, and several fundamental institutional investors.
georgie18
3月前
BEAT...9630...🥳
georgie18
Re: georgie18 post# 393
Friday, April 17, 2026 8:36:53 AM
Post#
395
of 395
BEAT...89s clearing here...🥳...bought the .80 range offering dip...
georgie18
Re: US Market News post# 392
Wednesday, April 15, 2026 8:45:37 AM
Post#
393
of 394
BEAT...88...🥳...Buying Dips on offering... HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock
April 14, 2026 10:00 PM
Business Wire
Offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock for total gross proceeds of $10 million, before deducting underwriting discounts, commissions, and offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions.
The offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, existing investors, and several fundamental institutional investors.
georgie18
3月前
BEAT...89s clearing here...🥳...bought the .80 range offering dip...
georgie18
Re: US Market News post# 392
Wednesday, April 15, 2026 8:45:37 AM
Post#
393
of 394
BEAT...88...🥳...Buying Dips on offering... HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock
April 14, 2026 10:00 PM
Business Wire
Offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock for total gross proceeds of $10 million, before deducting underwriting discounts, commissions, and offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions.
The offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, existing investors, and several fundamental institutional investors.
US Market News
3月前
HeartBeam Announces Closing of $10 Million Public Offering of Common StockApril 16, 2026 4:05 PM
Business Wire
Offering was led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced it has closed its underwritten public offering of 12,500,000 shares of common stock for total gross proceeds of $10 million before deducting underwriting discounts, commissions, and offering expenses. The closing of the offering occurred on April 16, 2026.
The offering was led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, existing investors, and several fundamental institutional investors.
HeartBeam intends to use the net proceeds received from the offering to support commercialization of its FDA-cleared 12-lead synthesized ECG system, advance development of its extended-wear patch and heart attack detection initiatives, further enhance its AI capabilities, and for working capital and general corporate purposes.
Titan Partners, a division of American Capital Partners, acted as the sole bookrunner for the offering.
This offering was made by HeartBeam pursuant to a shelf registration statement on Form S-3/A (File No. 333-293307) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 13, 2026, which became effective on March 17, 2026. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement was filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may also be obtained by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 49th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at prospectus@titanpartnersgrp.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
1Cleared Indications for Use
The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.
MKT-136 v.0
View source version on businesswire.com: https://www.businesswire.com/news/home/20260416675182/en/
Media Contact:
media@heartbeam.com
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Original: HeartBeam Announces Closing of $10 Million Public Offering of Common Stock
georgie18
3月前
BEAT...88...🥳...Buying Dips on offering... HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock
April 14, 2026 10:00 PM
Business Wire
Offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock for total gross proceeds of $10 million, before deducting underwriting discounts, commissions, and offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions.
The offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, existing investors, and several fundamental institutional investors.
US Market News
3月前
HeartBeam Announces Pricing of $10 Million Public Offering of Common StockApril 14, 2026 10:00 PM
Business Wire
Offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock for total gross proceeds of $10 million, before deducting underwriting discounts, commissions, and offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 16, 2026, subject to customary closing conditions.
The offering is being led by HeartBeam’s first commercial customer, ClearCardio™, the Company's executive leadership, board members, existing investors, and several fundamental institutional investors.
HeartBeam intends to use the net proceeds received from the offering to support commercialization of its FDA-cleared 12-lead synthesized ECG system, advance development of its extended-wear patch and heart attack detection initiatives, further enhance its AI capabilities, and for working capital and general corporate purposes.
“This financing provides us the capital to execute on our key strategic initiatives, as we expand the reach of our differentiated cardiac monitoring platform,” said Robert Eno, Chief Executive Officer of HeartBeam. “We are especially pleased to have ClearCardio™, our first commercial customer, join as an investor. Their participation meaningfully validates our technology and its fit within the high-engagement preventive cardiology and concierge markets, while reinforcing our confidence in the growing demand for more accessible, actionable cardiac insights.”
Titan Partners, a division of American Capital Partners, is acting as the sole bookrunner for the offering.
This offering is being made by HeartBeam pursuant to a shelf registration statement on Form S-3/A (File No. 333-293307) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 13, 2026, which became effective on March 17, 2026. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement will be filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 49th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at prospectus@titanpartnersgrp.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
1Cleared Indications for Use
The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.
MKT-135 v.0
View source version on businesswire.com: https://www.businesswire.com/news/home/20260414519110/en/
Media Contact:
media@heartbeam.com
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Original: HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock
US Market News
3月前
HeartBeam Announces Proposed Public Offering of Common StockApril 14, 2026 4:05 PM
Business Wire
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). All of the securities to be sold in the proposed offering will be offered by HeartBeam. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The Company intends to use the net proceeds from this offering to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, advance development of its extended-wear patch and heart attack detection initiatives, further enhance its AI capabilities, and for working capital and general corporate purposes.
Titan Partners, a division of American Capital Partners, is acting as the sole bookrunner for the proposed offering.
This offering is being made by HeartBeam pursuant to a shelf registration statement on Form S-3/A (File No. 333-293307) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 9, 2026, as amended, and declared effective by the SEC on March 17, 2026. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 49th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at prospectus@titanpartnersgrp.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
1Cleared Indications for Use
The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.
MKT-134 Rev.0
View source version on businesswire.com: https://www.businesswire.com/news/home/20260413898771/en/
Media Contact:
media@heartbeam.com
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Original: HeartBeam Announces Proposed Public Offering of Common Stock
US Market News
3月前
How Decentralized AI is Unlocking Value in Cardiac DiagnosticsMarch 27, 2026 9:30 AM
PR Newswire (US)
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER,BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the European Union over €282 billion annually while tragically claiming 1.7 million lives a year[1]. This immense structural pressure is acting as a catalyst for smart money, with institutional capital rapidly accumulating positions in scalable, AI-enabled diagnostic platforms. In fact, peer-reviewed data now confirms that AI-driven healthcare startups command the largest share of venture funding in the entire biopharmaceutical sector[2]. At the center of this pivotal transition are five companies building the infrastructure for the next cycle of predictive cardiology: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), HeartBeam (NASDAQ: BEAT), Heartflow (NASDAQ: HTFL), Hyperfine (NASDAQ: HYPR), and GE Healthcare Technologies (NASDAQ: GEHC).
This momentum is not just financial; it is heavily backed by the highest levels of medical regulation. The FDA's authorized registry of AI medical devices has just surpassed 1,200 approved products, with cardiovascular applications emerging as the second largest category overall[3]. This robust regulatory tailwind perfectly aligns with a severe clinical urgency. According to the landmark JACC Cardiovascular Statistics 2026 report, nearly half of all American adults now meet the criteria for hypertension. Because broader treatment and control rates have remained stagnant for over a decade, the market is making it clear that scalable, decentralized AI imaging solutions are the ultimate value drivers for this next healthcare cycle[4].VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is expanding into remote healthcare after announcing a partnership with First Light Health, an Indigenous-owned medical services company based in Vancouver, to deliver AI-powered cardiac diagnostics to Indigenous and remote communities across Canada.Together, the two companies are developing a hub-and-spoke care model built around VentriPoint's VMS+™ system. Local providers in remote areas will capture ultrasound scans on-site and be supported by specialists at a central hub who are able to digitally access images and assist with interpretation. That gives patients in British Columbia, Yukon, Alberta, Manitoba, and New Brunswick access to advanced cardiac imaging without travelling hundreds of kilometres, at lower cost and with faster turnaround than traditional referral pathways. Following validation of the model, Ventripoint plans to scale it beyond Canada into underserved communities globally.VentriPoint's VMS+™ system converts standard 2D echocardiograms into detailed 3D volumetric images. The company says its accuracy is comparable to cardiac MRI, but at a fraction of the cost and without the infrastructure those machines require. For communities where heart disease rates are high and specialist access is limited, the difference between early diagnosis and late diagnosis can be the difference between treatment and tragedy."Cardiovascular disease doesn't respect geography, but too often, access to cardiac care does," said Hugh MacNaught, CEO of VentriPoint Diagnostics. "Our work with First Light Health and other First Nations partners such as the Nisga_'a Valley Health Authority demonstrates the need for a made-in-Canada innovation that can close that gap. We see the potential for this solution to be widely deployed, from the Arctic to the Amazon. This is what scalable, equitable heart care looks like."First Light Health brings cultural safety expertise and established relationships within First Nations communities, which matters when deploying health technology in populations that have historically been underserved by the broader system.The partnership builds on recent commercial traction. VentriPoint signed a commercial agreement with LG Consulting Solutions to support VMS+™ deployment across Northern California, targeting cardiac centres in the Sacramento and San Francisco regions. Before that, the company had already partnered with the Nisga_'a Valley Health Authority to pilot a similar model in northern BC.VentriPoint is a Toronto-based medtech company with regulatory approvals in the United States, Canada, and Europe. Its VMS+™ platform works with ultrasound equipment from any vendor and is built on over a decade of Knowledge Based Reconstruction technology development. The goal is simple: put MRI-grade cardiac diagnostics within reach of any clinic or community that needs them.CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointIn other industry developments and happenings in the market include:HeartBeam (NASDAQ: BEAT) recently announced a strategic AI collaboration with the Icahn School of Medicine at Mount Sinai to jointly develop and validate next-generation AI-ECG algorithms using HeartBeam's patented 3D ECG platform, which is the only system capable of collecting synthesized 12-lead ECG data from patients in the home setting continuously over time. The partnership combines HeartBeam's longitudinal real-world ECG datasets with Mount Sinai's clinically annotated 12-lead data to accelerate training of personalized cardiac AI models for applications including heart attack risk assessment."We believe expanding access to 12-lead ECG data assessment beyond the clinic is one of the biggest opportunities," said Robert Eno, CEO of HeartBeam. "By pairing our ability to gather high-fidelity real-world ECG data with Mount Sinai's extensive clinical data resources and AI expertise, we are creating a differentiated cardiac intelligence engine that can scale beyond traditional care settings and broaden the reach of predictive cardiology, ultimately expanding our clinical and commercial opportunity."HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis in December 2025, providing a regulatory foundation for the expanded AI applications this collaboration targets. The resulting data engine is expected to support entry into new clinical indications and reimbursement pathways over time.Heartflow (NASDAQ: HTFL) announced new clinical evidence and a landmark registry launch at the American College of Cardiology Annual Scientific Session, with data from a 15,000-patient registry showing that high plaque volume independently predicts a fourfold increase in major adverse cardiovascular events regardless of conventional risk factors or stenosis severity. Simultaneously, Heartflow enrolled the first patient in the NAVIGATE-PCI Registry, a 5,000-patient study assessing the real-world impact of AI-guided CT-based pre-procedural planning on clinical strategy and physician confidence in the catheterization lab."These milestones reflect tremendous progress toward Heartflow's goal of transforming coronary artery disease from the world's leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life," said Campbell Rogers, M.D., F.A.C.C., Chief Medical Officer at Heartflow. "The Heartflow Plaque Analysis data presented at ACC and the launch of the NAVIGATE-PCI Registry represent important steps in building the rigorous real-world evidence needed to support AI-driven decision-making across the full continuum of cardiovascular care."Heartflow has now been adopted by more than 1,400 institutions globally and its technology is backed by over 600 peer-reviewed publications covering more than 500,000 patients. Commercial availability of the Heartflow PCI Navigator is expected in Q2 2026, positioning the company to expand its platform from risk stratification into guided intervention planning.Hyperfine (NASDAQ: HYPR) published breakthrough stroke detection data for its Swoop portable MRI system in the journal Stroke: Vascular and Interventional Neurology, with the next-generation scanner's advanced multi-directional DWI sequence achieving 100% sensitivity and 100% specificity for clinically relevant lesions greater than 1.0 mL, detecting strokes as small as 2.8 mm while cutting scan time by approximately 30%. The prospective multi-center study across Massachusetts General Hospital, Buffalo General Medical Center, and Yale New Haven Hospital represents the largest dataset to date evaluating portable MRI for stroke detection."Stroke detection represents a critical driver of the Swoop system's expansion into emergency departments," said Maria Sainz, President and CEO of Hyperfine. "The results from our next-generation Swoop system, combined with our new, advanced multi-direction DWI sequence that was recently cleared by the FDA, are truly remarkable. This data gives us even greater confidence that the Swoop system can reliably detect clinically relevant strokes, streamline workflows, and further strengthen the value of integrating portable MRI into stroke diagnosis and care."With FDA clearance for its multi-directional DWI sequence now secured and real-world performance validated across multiple clinical sites, Hyperfine is positioned to accelerate emergency department adoption of the Swoop platform. The system's portability and speed open new access pathways for stroke diagnosis in settings where conventional MRI is not clinically practical.GE Healthcare Technologies (NASDAQ: GEHC) announced its lead industrial role in COMPASS, a five-year, €50.5 million consortium backed by the European Union's Innovative Health Initiative and more than sixty partners focused on advancing early detection of cardiovascular toxicity in cancer patients across Europe. The program will leverage AI, advanced imaging, novel biomarkers, and integrated care pathways to address cardiotoxicity, which accounts for up to 10% of mortality in cancer survivors."This initiative is well positioned to enable patient-centered cancer care that takes cardiotoxicity risk into account, supports the early detection of cardiotoxic side-effects, and promotes long-term heart health for oncology patients," said Eigil Samset, General Manager, Cardiology Solutions at GE Healthcare and COMPASS Industry Lead. "By developing an AI-powered, integrated care pathway that connects oncologists and cardiologists in clinical practice, this collaboration has the potential to further improve cancer survival by tackling cardiovascular-related morbidity."The COMPASS grant agreement was signed on March 25, 2026 and runs for five years, with GE Healthcare positioned to advance its AI and imaging capabilities within the largest public-private healthcare partnership under the IHI framework. The initiative supports GE Healthcare's broader cardiology solutions strategy as part of its $20.6 billion global healthcare platform.Further Reading: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointCONTACT:USA NEWS GROUPinfo @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.oecd.org/en/publications/the-state-of-cardiovascular-health-in-the-european-union_ea7a15f4-en/full-report/the-burden-of-cardiovascular-disease_e28210c3.html
https://www.jmir.org/2026/1/e84968
https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices
https://www.jacc.org/doi/10.1016/j.jacc.2025.12.027Logo - https://mma.prnewswire.com/media/2838876/5886720/USA_News_Group_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/how-decentralized-ai-is-unlocking-value-in-cardiac-diagnostics-302726891.html
Original: How Decentralized AI is Unlocking Value in Cardiac Diagnostics
iHub News
4月前
HeartBeam Partners With Mount Sinai to Advance AI-Powered ECG TechnologyMarch 10, 2026 10:41 AM
IH Market News
HeartBeam (NASDAQ:BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai aimed at accelerating the development and clinical validation of next-generation artificial intelligence ECG algorithms.The partnership will combine HeartBeam’s patented ECG platform—which captures the heart’s electrical activity from three non-coplanar dimensions—with Mount Sinai’s clinical and artificial intelligence expertise to build advanced diagnostic tools.According to the company, “Under the collaboration, HeartBeam’s in-house AI team led by Lance Myers, PhD, a leading authority on AI applications in biosensor technologies, will work closely with Mount Sinai researchers to develop, train and validate a suite of advanced AI-ECG algorithms intended for deployment onto the HeartBeam platform.”The collaboration will involve several prominent cardiovascular and AI researchers from Mount Sinai. Joshua Lampert, MD, FACC—known for his work in AI-enabled cardiology and cardiovascular deep learning—will participate alongside Vivek Reddy, MD, a leading electrophysiologist and cardiac innovator. Girish N. Nadkarni, MD, MPH, Chief AI Officer of the Mount Sinai Health System and Chair of the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai, will also help guide the scientific and clinical direction of the project.HeartBeam said the joint effort is designed to enhance the diagnostic capabilities of its ECG platform and support the development of AI-driven tools that could improve the detection and monitoring of cardiac conditions.
More about HeartBeam
HeartBeam, Inc. is a medical technology company focused on advancing the detection and monitoring of serious cardiac conditions. The company is developing what it describes as the first cable-free device capable of collecting ECG signals in three non-coplanar directions and converting those signals into a synthesized 12-lead ECG.The platform is intended for portable use, allowing patients to capture ECG data outside of traditional medical settings and enabling physicians to remotely monitor heart health, identify trends and detect acute cardiac events.HeartBeam’s 3D ECG technology received U.S. Food and Drug Administration clearance for arrhythmia assessment in December 2024, followed by FDA clearance for its 12-lead ECG synthesis software in December 2025. The company holds more than 20 issued patents related to its technology platform.HeartBeam stock price
Original: HeartBeam Partners With Mount Sinai to Advance AI-Powered ECG Technology
subslover
4月前
HeartBeam and Mount Sinai Announce Strategic AI Collaboration to Bring Clinical-Grade Heart Monitoring into the Home
Accelerates development of personalized cardiac AI on the HeartBeam platform for wellness and clinical applications, including assessing heart attack risk
Combines Mount Sinai’s world-class AI and clinical expertise with HeartBeam’s groundbreaking 3D ECG signal collection technology
HeartBeam is the only platform capable of collecting 12-lead ECG data from patients anytime, anywhere, over time – extending access beyond traditional clinical settings
Positions HeartBeam to expand from symptom-based cardiac rhythm monitoring into AI-enabled disease assessment and management
SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the joint development and validation of next-generation AI-ECG algorithms. The collaboration will leverage HeartBeam’s patented ECG platform, which captures the heart’s electrical activity from 3 non-coplanar dimensions. The partnership marks a significant milestone in the Company’s long-term strategy to build an ecosystem around its platform and strengthen its leadership in AI-enabled cardiac monitoring.
A core value driver of the collaboration is HeartBeam’s differentiated ability to generate longitudinal, high-fidelity synthesized 12-lead ECG datasets from patients in the home setting—data that has historically been inaccessible to AI development. This creates a foundation for developing increasingly personalized algorithms earlier in the care journey and enabling 12-lead ECG assessments in real-world settings, supporting both wellness use cases and clinically relevant assessments, such as heart attack risk.
The combination of HeartBeam’s continuously expanding dataset and Mount Sinai’s clinically annotated 12-lead ECG data can accelerate the training and validation of various AI models. Over time, this collaboration will result in a data engine that is expected to support the development of increasingly personalized algorithms—positioning HeartBeam to expand into new clinical indications and reimbursement pathways.
“We believe expanding access to 12-lead ECG data assessment beyond the clinic is one of the biggest opportunities,” said Robert Eno, Chief Executive Officer of HeartBeam. “By pairing our ability to gather high-fidelity real-world ECG data with Mount Sinai’s extensive clinical data resources and AI expertise, we are creating a differentiated cardiac intelligence engine that can scale beyond traditional care settings and broaden the reach of predictive cardiology, ultimately expanding our clinical and commercial opportunity.”
Under the collaboration, HeartBeam’s in-house AI team led by Lance Myers, PhD, a leading authority on AI applications in biosensor technologies, will work closely with Mount Sinai researchers to develop, train and validate a suite of advanced AI-ECG algorithms intended for deployment onto the HeartBeam platform. Joshua Lampert, MD, FACC, a pioneer in AI-ECG and cardiovascular deep learning research and clinician recognized for his excellence in patient care, Vivek Reddy, MD, an internationally renowned electrophysiologist and innovator, and Girish N. Nadkarni, MD, MPH, the Chief AI Officer of the Mount Sinai Health System and Chair of the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai, will help guide the scientific and clinical development of the partnership.
“While AI-ECG has rapidly progressed as a field over recent years, there is room for improvement in the portability and scalability of such algorithms beyond acquisition devices that require complex multi-electrode systems. Additionally, current approaches struggle to leverage deep learning inference opportunities outside of traditional health care settings, which is where dynamic changes to cardiovascular health first start before patients present for care. The collaboration addresses these vital needs. By combining deep learning tools with the ability to record full 3-dimensional cardiac electrical activity without cables, we can provide clinically meaningful and operationally pragmatic models at scale regardless of environment,” said Dr. Lampert, Cardiac Electrophysiologist, Medical Director of Machine Learning for Mount Sinai Fuster Heart Hospital and Director of Cardiovascular Artificial Intelligence for the Windreich Department of Artificial Intelligence and Human Health at Mount Sinai.
Pairing HeartBeam’s innovative hardware and approach to cardiac waveform engineering with Mount Sinai’s advanced AI and clinical expertise creates a powerful foundation for developing tools that dynamically meet modern patient and clinician needs wherever they are.
“Heart disease doesn’t only show up during a brief visit to the clinic. This collaboration gives us an opportunity to bring powerful clinical-grade heart monitoring into patients’ daily lives,” said Dr. Nadkarni. “By combining advanced AI with HeartBeam’s ability to capture full 12-lead ECG signals from home over time, we can study the heart in ways that simply haven’t been possible before—helping clinicians detect risk earlier and guide care more precisely.”
“This collaboration addresses an important need by leveraging deep learning and 3-dimensional waveform data for scalable diagnostic and predictive purposes, allowing insights beyond even expert human ability,” added Dr. Reddy, who serves as the Director of Cardiac Arrhythmia Services for Mount Sinai Health System.
Together, the two organizations aim to accelerate the development of high-value algorithms that can be deployed broadly across HeartBeam’s platform. These AI models may include patient-relevant wellness insights, condition-focused assessments, and applications for chronic condition management. By enabling AI models to operate on longitudinal, real-world synthesized 12-lead ECG data rather than isolated clinical snapshots, the collaboration has the potential to significantly expand the addressable market for AI-driven cardiac monitoring. The collaboration could unlock new opportunities in preventive cardiology, chronic disease management, and remote patient monitoring—further reinforcing HeartBeam’s position as a leader in cardiac intelligence platforms.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 10 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2025-2026.
For more information, visit https://www.mountsinai.org/ or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.
About HeartBeam, Inc.
US Market News
4月前
HeartBeam to Host Fourth Quarter Full Year 2025 Results Conference Call on Thursday, March 12, 2026 at 4:30 p.m. Eastern TimeMarch 4, 2026 4:01 PM
Business Wire
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, March 12, 2026 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2025, and will be providing updates on its key strategic growth initiatives, specifically the limited commercial launch and significant developments on the 12-lead ECG extended wear patch. A press release detailing these results will be issued prior to the call.
HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. They will be joined on the call by HeartBeam’s recently appointed Chief Commercial Officer, Bryan Humbarger.
The conference call will be accompanied by a presentation and short video, which can be viewed during the webcast or accessed following the call via the investor relations section of the Company’s website here.
To access the call, please use the following information:
Date:
Thursday, March 12, 2026
Time:
4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-in:
1-844-826-3035
International Dial-in:
1-412-317-5195
Conference Code:
10206235
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1750485&tp_key=429593a446
A telephone replay will be available approximately three hours after the call and will run through March 26, 2026, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 10206235. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the Company’s investor relations section here.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam received FDA clearance for arrhythmia assessment for its 3D ECG technology in December 2024 and for its 12-Lead ECG synthesis software in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.
1Cleared Indications for Use
The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.
MKT-124 v1
View source version on businesswire.com: https://www.businesswire.com/news/home/20260304802595/en/
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Media Contact:
media@heartbeam.com
Original: HeartBeam to Host Fourth Quarter Full Year 2025 Results Conference Call on Thursday, March 12, 2026 at 4:30 p.m. Eastern Time
subslover
7月前
HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment
FDA Clearance Granted After Successful Appeal, Overturning Prior Not Substantially Equivalent (NSE) Outcome
HeartBeam’s Credit-Card Sized Device Delivers Clinical-Grade Insights Directly to Patients Anytime, Anywhere
Pivotal Milestone Unlocks Multiple Key Initiatives in Company’s Growth Strategy
SANTA CLARA, Calif.--(BUSINESS WIRE)--
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Company’s groundbreaking 12-lead electrocardiogram (ECG) synthesis software for the assessment of arrhythmias. This clearance follows HeartBeam’s successful appeal of a prior Not Substantially Equivalent (NSE) determination.
Unlike any single-lead or 6-lead consumer device, HeartBeam’s patented cable-free technology captures the heart’s electrical signals in three non-coplanar dimensions and synthesizes them into a 12-lead ECG representation. This allows patients to obtain an ECG reading for their arrhythmia from the comfort of home, or wherever they happen to be, representing a new level of convenience and peace of mind. The synthesized 12-lead ECG is promptly reviewed by an on-demand, board-certified cardiologist.
With this FDA clearance, the Company intends to advance several key initiatives as part of its growth strategy:
LIMITED LAUNCH: Initiate a market introduction in early 2026, focusing on select concierge and preventive cardiology groups that have proactively signaled strong interest in adopting HeartBeam’s technology. This limited market release will enable the Company to validate real world performance and establish reference sites for broader commercialization.
HEART ATTACK DETECTION: Pursue a heart attack detection indication, supported by compelling proof-of-concept data and representing a major expansion opportunity to tens of millions of patients in the U.S.
EXTENDED WEAR PATCH: Advance the on-demand 12-lead ECG extended wear monitor project. The Company has developed a working prototype of its novel 12-lead patch, which has the potential to be a best-in-class offering in an existing multi-billion-dollar market with reimbursement.
LONGITUDINAL DATA: Unlock the power of the unique data-rich repository generated from our 3D ECG platform. As adoption grows, the ability for patients to record synthesized 12-lead ECGs over time will create the opportunity to build AI-based screening and prediction algorithms that go beyond what is possible with single-timepoint ECGs or traditional wearables.
Robert Eno, Chief Executive Officer, HeartBeam commented, “The Company wishes to thank the FDA for its expeditious and constructive engagement throughout the review and appeal process, as well as its thorough evaluation of HeartBeam’s clinical data.
“This FDA clearance is a defining moment for HeartBeam, and the true beginning of our mission to revolutionize cardiac care. We look forward to initiating our U.S. market introduction while advancing our efforts on heart attack detection, an on-demand 12-lead extended wear patch, and AI-based screening and prediction algorithms trained on our unique longitudinal data.”
Robert A. Harrington, M.D., a world-renowned cardiologist and HeartBeam scientific advisory board member added, “One of the biggest challenges in cardiology is that cardiac symptoms most often don’t happen in the doctor’s office—they happen at home, at night, at work. The ability for patients to collect clinically meaningful ECG data at that exact moment, not hours later, can allow physicians to gain a much clearer understanding of a patient’s condition and take more timely action. HeartBeam is designed to be easy to carry and easy for patients to use, representing an important step forward in cardiac care.”
The Company plans to initiate a limited U.S. commercial launch in Q1 2026 with select concierge and preventive cardiology practices that have already signaled strong adoption interest. Additional details on broader geographic rollout, wearable integration, AI-enabled automated insights, and the Company’s heart attack detection program will be announced in the near future.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regar
Trooperstocks
1年前
$BEAT News Article Out: HeartBeam strengthens IP with US patents for cardiac monitoring
Medical Device Network-Global Data
Wed, May 7, 2025 at 10:10 AM EDT
In This Article:
BEAT, BEATW
HeartBeam has secured two new US patents, strengthening its intellectual property (IP) portfolio in cardiac monitoring technology.
The first patent pertains to the company’s cable-free three-dimensional (3D) electrocardiogram (ECG) device, which is roughly the size of a credit card.
The device has been tailored for convenience, incorporating chest and finger electrodes to capture high-fidelity electrical signals from three non-coplanar directions.
Individuals can use the device to record symptoms as they occur, regardless of their location.
The captured signals are synthesised into a 12-lead ECG through a personalised transformational matrix.
HeartBeam's 12-lead ECG synthesis software is undergoing US Food and Drug Administration (FDA) review.
The VALID-ECG pivotal study, which assessed the ECG in non-life-threatening arrhythmias, confirmed that the device met its clinical endpoints.
The second patent secures the company’s rhythm analysis algorithm, which can identify arrhythmias such as atrial fibrillation and sinus rhythm from continuous signal input.
It can be integrated into any cardiac monitoring system, including wearables, and facilitates risk-based escalation by identifying anomalies during passive monitoring.
The algorithm can prompt users to gather 3D ECG signals with the company’s device for a 12-lead ECG.
The company's portfolio now includes 20 issued patents across the US and internationally, two allowed and 32 pending patents.
HeartBeam CEO Robert Eno stated: “HeartBeam’s vision is to make it easier for patients and physicians to monitor and diagnose cardiac symptoms outside of a medical facility.
“The new patents add to our growing IP portfolio, enabling us to expand the reach and impact of our groundbreaking 3D ECG technology as we strive to transform the future of cardiac care.”
HeartBeam recently entered a partnership with AccurKardia, a company specialising in ECG-based diagnostics software, to enhance the accessibility of cardiac monitoring solutions.
In December 2024, HeartBeam's 3D ECG technology was granted FDA clearance for arrhythmia assessment.
"HeartBeam strengthens IP with US patents for cardiac monitoring" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Link: https://finance.yahoo.com/news/heartbeam-strengthens-ip-us-patents-141014886.html
Trooperstocks
1年前
$BEAT News: HeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent Portfolio
Business Wire
Tue, May 6, 2025 at 7:00 AM EDT
In This Article:
BEAT, BEATW
First patent significantly advances intellectual property for HeartBeam’s credit card-sized ECG device, bolstering both the defensive and offensive moat around the company’s core technology
Second patent expands the use of risk-based diagnostic algorithms into HeartBeam’s product portfolio around wearable devices
HeartBeam now has 20 issued patents worldwide, cementing Company’s leadership in cardiac monitoring innovation
SANTA CLARA, Calif., May 06, 2025--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the addition of two new U.S. patents, reinforcing its core intellectual property position and enabling future product extensions. The patents reinforce HeartBeam’s groundbreaking innovations and further solidify the Company’s intellectual property (IP) footprint in cardiac monitoring technology that bring advanced cardiac insights to patients and clinicians.
The first patent protects IP around HeartBeam’s credit card-sized, cable-free 3D ECG device. Designed for ease of use, the device features chest and finger electrodes to capture high-fidelity electrical signals in 3D (by capturing 3 non-coplanar directions) – enabling patients to record their symptoms the moment they occur, wherever they are. The signals are then synthesized into a familiar 12-lead ECG using a personalized transformational matrix. The 12-lead ECG synthesis software is currently under review with the FDA. Data from the VALID-ECG pivotal study supporting the FDA submission was presented at the Heart Rhythm Society conference in April 2025.
The second patent protects HeartBeam’s rhythm analysis algorithm, which distinguishes between sinus rhythm, atrial fibrillation, and other arrhythmias using continuous signal input. Designed to operate on any cardiac monitoring system including wearables, the algorithm enables risk-based escalation by detecting anomalies during passive monitoring and prompting the user to collect high-fidelity 3D ECG signals with HeartBeam’s credit card-sized device, enabling synthesis of a 12-lead ECG.
"HeartBeam’s vision is to make it easier for patients and physicians to monitor and diagnose cardiac symptoms outside of a medical facility. The new patents add to our growing IP portfolio, enabling us to expand the reach and impact of our groundbreaking 3D ECG technology as we strive to transform the future of cardiac care," said Robert Eno, Chief Executive Officer of HeartBeam.
With these two new U.S. patents, HeartBeam now holds 20 issued US and international patents, as well as 2 allowed patents and 32 pending patents, adding to an already robust IP portfolio that supports the company’s differentiated position in remote cardiac diagnostics. These innovations lay the groundwork for future capabilities such as AI-driven classification algorithms and ischemia detection, further extending HeartBeam’s potential to provide unprecedented cardiac insights to individuals and physicians.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first ever cable-free device capable of collecting ECG signals in 3D, from 3 non-co-planar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The Company holds 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250506303008/en/
Contacts
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Media Contact:
media@heartbeam.com
Trooperstocks
1年前
$BEAT News: HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth
Business Wire
Mon, May 5, 2025 at 7:00 AM EDT
In This Article:
BEAT, BEATW
Board expansion reflects Company’s commitment to leadership and innovation in remote cardiac monitoring
SANTA CLARA, Calif., May 05, 2025--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition.
Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven track record of developing markets and launching disruptive medical technologies. His leadership has been instrumental as HeartBeam prepares to commercialize its groundbreaking 3D ECG technology, which captures the heart’s electrical signals in 3 non-coplanar directions and then synthesizes these signals into a 12-lead ECG.
Rich Ferrari, Executive Chairman, Board of Directors of HeartBeam, commented, "Rob’s deep expertise in sales and go-to-market strategies perfectly complements the diverse skillset and experience of the Board and strengthens our strategic oversight as we move toward commercialization and long-term growth. We are confident that Rob’s perspective will be instrumental in helping HeartBeam achieve its vision of delivering powerful cardiac insights wherever the patient is."
HeartBeam received FDA clearance for its patented 3D ECG technology in December 2024 and submitted an FDA application for the 12-lead ECG synthesis software in January 2025. The Company plans to initiate commercialization upon receiving FDA clearance for the 12-lead ECG synthesis software. Earlier this year, the Company initiated an Early Access Program to obtain important feedback on the end-to-end clinical workflow, ensure operational readiness and establish an early adopter funnel.
"I am honored to join the HeartBeam Board as we are on the brink of bringing HeartBeam’s novel technology to market," said Mr. Eno. "I look forward to working closely with my fellow Board members as we leverage our diverse expertise to drive the Company’s commercial success and accelerate the Company’s mission to transform the way cardiac health is managed."
Prior to joining HeartBeam, Mr. Eno served as CEO of Preview Medical, a diagnostic equipment company developing real-time, in vivo tissue classification for solid tumor cancers using machine learning and proprietary optical signals. He also held senior marketing and sales leadership roles at companies including HeartFlow, OptiMedica, NeoGuide Systems, and Avantec Vascular. Mr. Eno holds an MBA from the Stanford Graduate School of Business and a BA, with Honors and Distinction, from Stanford University.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first ever cable-free device capable of collecting ECG signals in 3D, from 3 non-co-planar directions, and synthesizes the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The Company holds 14 U.S. and 4 international issued patents related to technology enablement. For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250503355887/en/
Contacts
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Media Contact:
media@heartbeam.com
Hot Features
プレミアム
ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
Boing x 2
4月前
glenn1919
4月前
INV4
7月前
TrendTrade2016
7月前
bikaver
7月前
メールアドレスで登録
